ANI Pharmaceuticals (NASDAQ:ANIP) had its price objective reduced by Raymond James from $82.00 to $75.00 in a research note released on Thursday, Stock Target Advisor reports. They currently have an outperform rating on the specialty pharmaceutical company’s stock.
Several other equities analysts have also recently weighed in on the company. Guggenheim began coverage on ANI Pharmaceuticals in a research report on Thursday, September 12th. They set a buy rating and a $76.00 price objective for the company. ValuEngine cut ANI Pharmaceuticals from a sell rating to a strong sell rating in a report on Thursday. BidaskClub raised ANI Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, October 22nd. Finally, Zacks Investment Research raised ANI Pharmaceuticals from a sell rating to a hold rating in a report on Friday, October 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $85.00.
Shares of ANIP stock traded down $4.05 on Thursday, reaching $57.38. 388,900 shares of the company’s stock traded hands, compared to its average volume of 137,916. ANI Pharmaceuticals has a 12-month low of $36.92 and a 12-month high of $86.96. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.74 and a current ratio of 1.01. The company has a market capitalization of $954.49 million, a P/E ratio of 12.45 and a beta of 2.20. The business’s 50 day moving average price is $73.65 and its two-hundred day moving average price is $73.58.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.20). ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The business had revenue of $51.30 million for the quarter, compared to analyst estimates of $56.10 million. During the same period in the prior year, the firm posted $1.29 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 1.2% on a year-over-year basis. Research analysts predict that ANI Pharmaceuticals will post 5.29 earnings per share for the current year.
In other ANI Pharmaceuticals news, major shareholder Meridian Venture Partners Ii L sold 7,579 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $68.21, for a total value of $516,963.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 78,591 shares of company stock valued at $5,582,839. Insiders own 24.70% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of ANI Pharmaceuticals by 5.1% in the 2nd quarter. BlackRock Inc. now owns 1,429,732 shares of the specialty pharmaceutical company’s stock valued at $117,524,000 after purchasing an additional 69,621 shares during the period. Vanguard Group Inc. grew its stake in shares of ANI Pharmaceuticals by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 564,317 shares of the specialty pharmaceutical company’s stock valued at $46,387,000 after purchasing an additional 12,859 shares during the period. Nomura Holdings Inc. grew its stake in shares of ANI Pharmaceuticals by 34.1% in the 2nd quarter. Nomura Holdings Inc. now owns 375,449 shares of the specialty pharmaceutical company’s stock valued at $31,071,000 after purchasing an additional 95,462 shares during the period. First Manhattan Co. grew its stake in shares of ANI Pharmaceuticals by 22.8% in the 2nd quarter. First Manhattan Co. now owns 294,852 shares of the specialty pharmaceutical company’s stock valued at $24,236,000 after purchasing an additional 54,686 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of ANI Pharmaceuticals by 44.6% in the 2nd quarter. Renaissance Technologies LLC now owns 288,100 shares of the specialty pharmaceutical company’s stock valued at $23,682,000 after purchasing an additional 88,900 shares during the period. Institutional investors own 70.97% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Story: What is a Swap?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.